Intuitive Surgical (NASDAQ:ISRG) Given New $425.00 Price Target at Evercore ISI

Intuitive Surgical (NASDAQ:ISRG) had its price target lifted by Evercore ISI from $385.00 to $425.00 in a research note released on Tuesday, Benzinga reports. They currently have an in-line rating on the medical equipment provider’s stock.

A number of other research analysts have also recently weighed in on ISRG. Piper Sandler boosted their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an overweight rating in a research report on Friday, April 19th. Stifel Nicolaus boosted their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a buy rating in a research report on Monday, April 8th. Jefferies Financial Group boosted their price objective on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a hold rating in a research report on Friday, April 19th. Citigroup boosted their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a buy rating in a research report on Wednesday, April 3rd. Finally, The Goldman Sachs Group assumed coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They set a buy rating and a $500.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $404.79.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $438.81 on Tuesday. The company’s fifty day moving average is $405.17 and its 200 day moving average is $384.28. Intuitive Surgical has a fifty-two week low of $254.85 and a fifty-two week high of $448.10. The stock has a market capitalization of $155.65 billion, a PE ratio of 79.21, a P/E/G ratio of 5.75 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the previous year, the business posted $1.00 earnings per share. Intuitive Surgical’s quarterly revenue was up 11.5% on a year-over-year basis. As a group, research analysts forecast that Intuitive Surgical will post 4.8 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Myriam Curet sold 5,318 shares of the company’s stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total value of $1,971,169.88. Following the completion of the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at $110,456.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Intuitive Surgical news, EVP Myriam Curet sold 5,318 shares of the stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the sale, the executive vice president now directly owns 298 shares of the company’s stock, valued at $110,456.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mark Brosius sold 175 shares of the stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $389.16, for a total transaction of $68,103.00. Following the sale, the senior vice president now directly owns 883 shares of the company’s stock, valued at $343,628.28. The disclosure for this sale can be found here. Insiders sold a total of 17,956 shares of company stock valued at $6,927,011 over the last three months. 0.90% of the stock is owned by company insiders.

Institutional Trading of Intuitive Surgical

Several hedge funds have recently modified their holdings of the company. Marcum Wealth LLC increased its holdings in shares of Intuitive Surgical by 1.7% during the second quarter. Marcum Wealth LLC now owns 2,660 shares of the medical equipment provider’s stock valued at $1,183,000 after acquiring an additional 44 shares in the last quarter. Massmutual Trust Co. FSB ADV increased its holdings in shares of Intuitive Surgical by 13.8% during the second quarter. Massmutual Trust Co. FSB ADV now owns 1,058 shares of the medical equipment provider’s stock valued at $471,000 after acquiring an additional 128 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Intuitive Surgical by 38.3% during the second quarter. GAMMA Investing LLC now owns 3,879 shares of the medical equipment provider’s stock valued at $1,726,000 after acquiring an additional 1,075 shares in the last quarter. Transcend Capital Advisors LLC increased its holdings in shares of Intuitive Surgical by 197.6% during the second quarter. Transcend Capital Advisors LLC now owns 3,315 shares of the medical equipment provider’s stock valued at $1,475,000 after acquiring an additional 2,201 shares in the last quarter. Finally, Objective Capital Management LLC increased its holdings in shares of Intuitive Surgical by 11.8% during the first quarter. Objective Capital Management LLC now owns 728 shares of the medical equipment provider’s stock valued at $291,000 after acquiring an additional 77 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.